This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's How Colgate (CL) is Poised Ahead of Q1 Earnings
by Zacks Equity Research
Colgate's (CL) first-quarter 2023 sales are likely to have gained from innovation, brand strength, focus on premiumization and expansion efforts.
Clorox (CLX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Clorox (CLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Beat the Market Like Zacks: NVIDIA, Clorox, Procter & Gamble in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Will Clorox (CLX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Clorox (CLX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Take the Zacks Approach to Beat the Market: NVIDIA, Novo Nordisk, Magenta in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Here's Why Investors Should Hold Colgate (CL) Stock for Now
by Zacks Equity Research
Pricing actions, revenue management initiatives, innovation, brand strength and digital growth position Colgate (CL) for growth amid higher costs and currency headwinds.
Clorox (CLX) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Beat the Market Like Zacks: NVIDIA, SoundHound, Reuters in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Are Consumer Staples Stocks Lagging Clorox (CLX) This Year?
by Zacks Equity Research
Here is how Clorox (CLX) and Coca-Cola FEMSA (KOF) have performed compared to their sector so far this year.
Clorox (CLX) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Clorox (CLX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks Industry Outlook Highlights The Procter & Gamble, Colgate-Palmolive, Henkel AG, Church & Dwight and The Clorox
by Zacks Equity Research
The Procter & Gamble, Colgate-Palmolive, Henkel AG, Church & Dwight and The Clorox are part of the Zacks Industry Outlook article.
Take the Zacks Approach to Beat the Market: Uber, Baidu, AssetMark in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
5 Soaps & Cleaning Materials Stocks to Watch as Industry Catches Pace
by Rajani Lohia
The soap and cleaning materials industry looks poised for growth on robust demand, pricing initiatives, innovation, digital transformation and brand building, while elevated costs remain headwinds. Players like PG, CL, HENKY, CHD and CLX seem well-poised.
The Zacks Analyst Blog Highlights Cardinal Health, The Coca-Cola, General Mills, The Clorox and Cincinnati Financial
by Zacks Equity Research
Cardinal Health, The Coca-Cola, General Mills, The Clorox and Cincinnati Financial are part of the Zacks top Analyst Blog.
Here's Why Clorox (CLX) is Marching Ahead of Its Industry
by Zacks Equity Research
Despite inflation concerns, Clorox (CLX) looks well poised to drive growth in the future on the back of solid demand, pricing actions, cost savings efforts and other growth strategies.
5 Safe Stocks to Buy as SVB Collapse Shakes Wall Street
by Nalak Das
At this stage, it will be prudent to stay with safe stocks.Five such stocks are: CAH, CINF, CLX, KO and GIS.
5 Consumer Staples Stocks to Buy as Volatility Grips Markets
by Nalak Das
We have narrowed our search to five consumer staples stocks with strong potential for 2023. These are: CLX, GIS, KO, HSY and CHWY.
Powell's Hawkish Tone Rattles Wall Street: 5 Ultra-Safe Picks
by Tirthankar Chakraborty
With Powell's hawkish comments flaring up volatility, it is prudent to invest in risk-adjusting stocks like Unitil (UTL), Xcel Energy (XEL), NiSource (NI), Clorox (CLX) & Ingredion (INGR) for steady returns.
Solid Demand to Aid Archer Daniels (ADM) Amid Inflation
by Zacks Equity Research
Archer Daniels (ADM) is likely to continue gaining from healthy demand, strength in the Nutrition unit, portfolio expansion and strategic partnerships. However, inflationary pressure is concerning.
Is Clorox (CLX) Stock Outpacing Its Consumer Staples Peers This Year?
by Zacks Equity Research
Here is how Clorox (CLX) and Coca-Cola FEMSA (KOF) have performed compared to their sector so far this year.
Take the Zacks Approach to Beat the Market: NVIDIA, Block, Clorox in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Take the Zacks Approach to Beat the Market: Ulta Beauty, Clorox, Similarweb in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Clorox (CLX) Q2 Earnings and Sales Beat, Stock Rises 4.2%
by Zacks Equity Research
Clorox's (CLX) Q2 results reflect gains from strong demand trends, improved pricing, cost savings and strong execution, offset by lower volume and higher commodity costs.
Here's What Key Metrics Tell Us About Clorox (CLX) Q2 Earnings
by Zacks Equity Research
The headline numbers for Clorox (CLX) give insight into how the company performed in the quarter ended December 2022, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Clorox (CLX) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Clorox (CLX) delivered earnings and revenue surprises of 50.77% and 2.96%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?